Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.
Lesven
S
S
CHU de la Cavale-Blanche, Brest, France. sandra.lesven@chu-brest.fr
Gautier
J-F
JF
Maréchaud
R
R
D000818:Animals; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000473:pathology*; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000473:pathology*; D052216:Glucagon-Like Peptide 1 / Q000627:therapeutic use*; D006331:Heart Diseases / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D052216:Glucagon-Like Peptide 1